DiscoverCME in Minutes: Education in Cardiology & PulmonologyPasi A. Jänne, MD, PhD - Expanding Pathways of Care for HER2-Positive Metastatic NSCLC: Beyond Mutation to Overexpression
Pasi A. Jänne, MD, PhD - Expanding Pathways of Care for HER2-Positive Metastatic NSCLC: Beyond Mutation to Overexpression

Pasi A. Jänne, MD, PhD - Expanding Pathways of Care for HER2-Positive Metastatic NSCLC: Beyond Mutation to Overexpression

Update: 2025-01-02
Share

Description

Please visit answersincme.com/GRK860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in medical oncology discusses the role of antibody–drug conjugates (ADCs) in the treatment of HER2-positive metastatic non–small-cell lung cancer (NSCLC). Upon completion of this activity, participants should be better able to: Recognize the difference between HER2 overexpression and HER2 mutation when managing patients with advanced NSCLC; Review the efficacy and safety of HER2-directed antibody–drug conjugates (ADCs) for the treatment of HER2-overexpressing metastatic NSCLC; and Outline clinical approaches to optimize the management of patients with HER2-overexpressing metastatic NSCLC.
Comments 
loading
In Channel
loading
00:00
00:00
1.0x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Pasi A. Jänne, MD, PhD - Expanding Pathways of Care for HER2-Positive Metastatic NSCLC: Beyond Mutation to Overexpression

Pasi A. Jänne, MD, PhD - Expanding Pathways of Care for HER2-Positive Metastatic NSCLC: Beyond Mutation to Overexpression

Answers in CME